

MCX/SEC/2639

February 10, 2026

Listing Department
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai 400001

Scrip code: 534091, Scrip ID: MCX

Subject: Intimation on publication of newspaper advertisements

Dear Sir/Madam,

Please find enclosed copy of the newspaper advertisement published in 'Times of India', 'The Economic Times', 'Mint' and 'Business Standard' on Tuesday, January 10, 2026, *inter alia*, inviting applications for the key positions of Executive Directors, pursuant to SEBI Circular dated December 12, 2025.

The same will also be available on the website of the Company at www.mcxindia.com

Kindly take the same on record.


Thanking you,

Yours faithfully,

For Multi Commodity Exchange of India Limited

Manisha Thakur

Manisha Thakur
Company Secretary



Encl: as above

Wangchuk getting proper med care in custody: Govt

Opposes Review Of Activist's Detention In SC

AmitAnand.Choudhary
@timesofindia.com



There is nothing in Ladakh to care for Wangchuk's health, ASG told SC

New Delhi: Centre on Monday expressed its dissatisfaction towards review of detention of climate activist Sonam Wangchuk on medical grounds saying that he was getting proper treatment in custody by AIIMS Jodhpur and there is "nothing" in Ladakh to care for his health. Though the govt is yet to take a final decision, the response came when SC asked its last suggestion given in the last hearing on the review.

When additional solicitor-general KMNatala paled a batch of Justices Aravind Kumar and P B Varale to adjourn the hearing, the court asked him whether there was any progress on its suggestion made on the last hearing regarding release of detention. "Any progress?" We made a suggestion on the last date," the bench asked.

The AG said that he would submit on the issue when he argued his case and the final decision would be taken.

He told the court that the activist was getting the best of treatment.

When the court told ASG that it had made the suggestion because of his medical issues and the govt was also aware about it, the AG said that the activist was being ta-

ken care of by AIIMS Jodhpur and there was nothing in Ladakh to care for his health.

"There are issues, and it is not like you are denying it, and he is also making a complaint of health issues. The doctor says yes, it is there, and now treatment is being given," said Aravind. The health issue is there, the bench observed. Observing that the medical condition of Wangchuk, who has been in detention for more than four months, was not very good, SC last week had asked the Centre to rethink/relook its decision to continue to keep him in custody.

The activist is presently lodged in Jodhpur jail. Wangchuk was detained on Sept 20, 2025 under National Security Act (NSA) following protest in Leh over demands of statehood and Sixth Schedule status for the Union Territory of Ladakh.

SC is hearing the plea moved by Wangchuk's wife Gitanjali Angmo against his preventive detention.

HC judges cannot assume domain experts' role: SC

Dhananjay.Mahapatra
@timesofindia.com

New Delhi: Supreme Court on Monday cautioned constitutional court judges against assuming the role of domain experts and suggesting remedial steps and said it would be dangerous if they deviate from their primary duty to decide disputes as neutrals and often interfere in pending civil submissions.

"DANGEROUS IF THEY INTERFERE IN EXAMS" The remark came from a batch of Chief Justice Surya Kant, Justices Jayajyoti Bagchi and NV Anjaria on a petition filed by Jharkhand Public Service Commission (JPSC) challenging Jharkhand HC's decision to direct deletion of two questions and award of one mark to either of two options to a question attempted by candidates appearing in a preliminary test for recruitment of ju-

dicial officers.

CJI Kant said, "Should a constitutional court assume the role of domain experts just because the test was for recruitment of judicial officers and the question related to law? It will be very dangerous if HC judges assume the role of domain experts."

"If that is so, it is necessary that HC, while exercising the power of judicial review, should have referred the issue to the administrative side of HC for constituting an expert committee to assist the answer sheets and answer keys," the bench said.

The bench asked HC to set up an expert committee that will include subject experts from the fields of law and English, to reevaluate the answer keys and answer sheets.

When the counsel sought an early resolution of the controversy, the bench asked high court to resolve it within two weeks and send a report to JPSC.

"The power of reappre-

cation/reconsideration of answer sheets must be uniform for all examinations and not limited to service tests. HC cannot be a party-examiner," it said.

"If that is so, it is necessary that HC, while exercising the power of judicial review, should have referred the issue to the administrative side of HC for constituting an expert committee to assist the answer sheets and answer keys," the bench said.

The bench asked HC to set up an expert committee that will include subject experts from the fields of law and English, to reevaluate the answer keys and answer sheets.

When the counsel sought an early resolution of the controversy, the bench asked high court to resolve it within two weeks and send a report to JPSC.

"The power of reappre-

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

• EXECUTIVE DIRECTOR Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

• EXECUTIVE DIRECTOR Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

• EXECUTIVE DIRECTOR Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026



LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under Section 18 of the Securities (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MII).

MCX
METAL & ENERGY
Trade with Trust

Scan to learn more about the roles and how to apply



NRB BEARINGS THE ORIGINAL
We Make Things Move

Quarterly Highlights Y-o-Y

STANDALONE CONSOLIDATED



S.No.	Particulars	STANDALONE				Year ended 31.03.2025
		Quarter Ended 31.12.2025	30.09.2025	31.12.2024	31.12.2025	
1	Total Income	30,026	30,736	26,437	89,544	89,585
2	Profit before exceptional items and tax	4,006	4,541	2,927	12,170	8,877
3	Profit after tax	2,397	3,645	1,821	8,682	6,379

1. The above results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 09 February 2026.

2. The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under the Companies (Ind AS) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standard) (Amendment) Rule, 2016.

Note: The above is an extract of the detailed format of Financial Results for the quarter and nine months ended 31 December 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Yearly Financial Results are available on the websites of BSE <http://www.bseindia.com> and NSE <http://www.mseindia.com> and also on Company's website at <http://www.nrbe.com>.

For and on behalf of the Board of Directors
Place : Mumbai
Date : 09.02.2026

For and on behalf of the Board of Directors
(Ms) Sharbeena Zaveri
Vice-Chairman & Managing Director
DIN No. 00003748

NRB BEARINGS LIMITED
Registration Number: 20040102200000000000
For and on behalf of the Board of Directors
Tel: 022 23460100, Fax: 022 23460102, Email: investorrelations@nrbe.com
website: www.nrbe.com



Often, payments made in haste
can lead to your money going to waste.

Always check the identity of the person
before sending any funds in a hurry
aur koi aapke saath hera pheri karne ki koshish kare,
then just say, "Main moork nahi hoon".

Safety UPI ki, samajhdaari aapki.

UPI
UNIFIED PAYMENTS INTERFACE
Easy. Safe. Instant.

Issued in public interest by
NPCI
NATIONAL PAYMENTS CORPORATION OF INDIA

Report cyber financial fraud on helpline no. 1930.

lgthr/12/24/061

Ajanta Eyes 2k-cr Fundraise for Burger King Franchisee

Pharma co likely to opt for promoter-level borrowing and debt to fund the deal

Shilpy Sinha

Mumbai: Ajanta Pharma's promoters are exploring financing options of up to ₹2,000 crore to fund the acquisition of a controlling interest in Restaurant Brands Asia and India and Indonesia franchisees of Burger King, in a transaction that would mark the drugmaker's diversification into the fast-growing quick service restaurant sector. The promoters group is looking to raise about ₹2,000 crore through a combination of promoter-level borrowing and debt at the operating company according to people familiar with the discussions.

The financing structure is still being finalised and no letter has been formally applied for yet, people said.

Barclays and Standard Chartered are among banks that have been sounded out for the funding, though talks remain at a preliminary stage. The individual banks and the companies did not respond to ET's requests for comment. The fundraise is al-

Diversification Drive

WHY THE FUND RAISE
To back the acquisition of a controlling interest in Restaurant Brands Asia
PE firm Everstone Capital is preparing to exit its entire 11.26% stake

- MONEY TO BE RAISED VIA**
- Promoter-level borrowing
- Debt at operating company



mosted at backing the acquisition of a controlling interest in Restaurant Brands Asia, where private equity firm Everstone Capital is preparing to exit its entire 11.26% stake. Restaurant Brands Asia has a 11.26% stake in Inspira Global. Lexenis expects to sell its 11.26% stake in the food and beverage arm of Inspira Global, which is promoted by Anupam Mehta, Anil and Madhushan Agrawal, members of the Ajanta Pharma promoter family. Inspira Global has interests spanning food and beverage, real estate, pharma, luxury hospitality and energy.

Restaurant Brands Asia, formerly Burger King India, holds major franchise rights for Burger King in India and operates Burger King and Popeyes restaurants in India. The financing comes as Ajanta Pharma's promoter group already carries pledged shares.

Marico to Buy 75% in Vietnam's Skinetiq

Mumbai: Marico on Monday said it will acquire 75% equity stake in Vietnamese direct to consumer beauty and personal care company Skinetiq Joint Stock Company, based on an equity valuation of ₹350 crore.

The company's subsidiary Marico South-East Asia Corporation will acquire 75% of Skinetiq's total shares from its existing shareholders and it can acquire Skinetiq's remaining shares after FY22, given the achievement of requisite milestones. — Our Bureau



ET CAMPUS SPOTLIGHT

Chetana College to Host "Digital Marginalization and AI Bias: Redefining Business and Society" Meet

Chetana's Hazarimal Somani College of Commerce and Economics, along with Smt. Kusumtai Chaudhari College of Arts and Chetana's Rampsradh Khandelwal Institute of Management & Research, Bandra (E), will jointly host a two-day International Conference on "Digital Marginalization and AI Bias: Redefining Business and Society" on 27-28 February 2024. Sponsored by the Indian Council of Social Science Research (ICSSR), the conference aims to foster global dialogue on the social, ethical, and economic implications of artificial intelligence and digital inequality. The forum will bring together academics, researchers, policy-makers, industry leaders, and students from India and abroad to deliberate on algorithmic bias, access gaps, inclusive technologies, and ethical AI governance. Hon. Suresh Prabhu will grace the inaugural session as chief guest, with a keynote by Mr Vivek Sawant. International speakers including Mr Nick Hutton, Dr Mohammad Rami Al Jundi, and Dr Kyung Ki Eun, alongside Indian experts, will share insights on responsible and equitable AI-driven transformation.

"Wednesday morning stays clear. Let's meet later."

Manjari Upadhye,
CMO-Auto,
Mahindra & Mahindra Ltd.

Brand Equity is here in a fresh, new avatar. Now with sharper insights, bolder opinions and compelling stories from the voices that matter. So, if you have something planned for Wednesday morning, we'd suggest you cancel it.



Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

EXECUTIVE DIRECTOR Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR

Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment and is listed under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MII).



#ConmanVsCommonMan



Often, payments made in haste can lead to your money going to waste.

Always check the identity of the person before sending any funds in a hurry aur koi aapke saath hera pheri karne ki koshish kare, then just say, "Main moorkh nahi hoon".

Safety UPI ki, samajhdaari aapki.



Easy. Safe. Instant.



Issued in public interest by

NATIONAL PAYMENTS CORPORATION OF INDIA

Report cyber financial fraud on helpline no.1930.

lghtr/12/24/061

Tata Steel hunts for iron ore as legacy mines' leases to end

Firm meets 100% of iron ore needs from six legacy mines, but leases start expiring from 2030

Deepa Srivastava/Hindustan Times

Forums, like one on Wednesday, Tata Steel's current live along more than 100 legacy supplier mines, are in a state of edge over the time it depends on open-pit mines acquired through auctions or partnerships.

This is, however, an advantage, as the company will lose the edge when its legacy mining leases begin to expire starting 2030. To meet its total supply for iron ore, the key raw material in its steelmaking, Tata Steel has to look outside, and that stretches from the cold mountains of Labrador in Canada to the Gaikwad forests in Maharashtra.

"Maharashtra, Canada, all these are areas to post 2030," T. V. Narendran, managing director and chief executive officer of Tata Steel, said during a news conference in Mumbai on Monday. "So doing this, the company's efforts at securing iron ore supplies. This, he said, was in addition to the time it has acquired in its business.

Tata Steel's oldest stakeholder in India, currently meets 20% of its iron ore requirements in India through its six legacy mines, awarded to it before the Mines and Minerals Development and Regulation Act (MMDRA) in 2013, which provides all mines to be auctioned, those that are auctioned by the government.

India's second largest steelmaker has joined hands with a key player in the industry, a Canadian consortium, who has agreed to successfully mine less ore—and will soon be making it available from this area—in a MoU to confine the region that few businesses dared to venture into.

Earlier, Tata Steel, a stakeholder in Tata Steel's oldest stakeholder in India, currently meets 20% of its iron ore requirements in India through its six legacy mines, awarded to it before the Mines and Minerals Development and Regulation Act (MMDRA) in 2013, which provides all mines to be auctioned, those that are auctioned by the government.

Tata Steel's second largest steelmaker has joined hands with a key player in the industry, a Canadian consortium, who has agreed to successfully mine less ore—and will soon be making it available from this area—in a MoU to confine the region that few businesses dared to venture into.

Earlier, Tata Steel, a stakeholder in Tata Steel's oldest stakeholder in India, currently meets 20% of its iron ore requirements in India through its six legacy mines, awarded to it before the Mines and Minerals Development and Regulation Act (MMDRA) in 2013, which provides all mines to be auctioned, those that are auctioned by the government.



The legacy stake from the 2013 MMDRA auction, which remained unmet, says T. V. Narendran, CEO, Tata Steel.

POST-2030 PLAYBOOK

THE firm is mulling options to meet its Canadian customers' needs in Canada and elsewhere in the Americas.

More importantly, the stakeholder also signed an agreement of underwriting with a local Maharashtra-based company for mining opportunities in Maharashtra to increase the production of iron ore. "We are seeking opportunities in the Maharashtra government,"

WITH the N. Tata Steel's 100% stake in its 100% owned subsidiary, it has signed a joint venture agreement to evaluate suitability for local iron ore mining.

The stakeholder has also tapped into its Canadian subsidiary, Tata Steel Canada, to explore opportunities in Canada. "We are evaluating opportunities from Canada for its domestic operations. After half reported earlier, while the statement is yet to reach

India's share, it could be one of the solutions to the firm's iron ore needs beyond 2030," Narendran said.

The stakeholder has also tapped into its Canadian subsidiary, Tata Steel Canada, to explore opportunities in Canada. "We are evaluating opportunities from Canada for its domestic operations. After half reported earlier, while the statement is yet to reach

Easing aircraft supply puts Akasa back on growth path

Deepa Srivastava/Hindustan Times



Akasa Air's deliveries have become more predictable, marking an inflection point for Akasa Air after two years of disruptions across

aircraft supply constraints.

"So it's a thing of

past," said Leon Dube, the founder and chief executive officer of Akasa Air, in an interview with Mint. Blue, referring to aircraft, is a color that Akasa Air uses for its aircraft.

"The aircrafts are

more easily identifiable, and we know them better."

Akasa, which operates an fleet of 10 aircraft, has been

able to meet its

aircraft delivery

schedule, which

was not the case

two years ago.

"We are off

the ground

now," Dube said.

With aircraft

delivered

on time, Akasa

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

Akasa has

restarted pilot

hiring after a

18-month pause,

initially focusing

on experienced

first officers

aircrafts are

more predictable,

marking an

inflection point

for Akasa Air after two years of disruptions across

highly time sensitive

aircrafts and

aircraft delivery

schedule."

With aircraft

delivered

on time, Akasa

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

acquisition,"

he said.

"Akasa Air

is now

able to

focus on

expansion

and

customer

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANJALI SINGH
Mumbai, 10 February

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation.

They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.

Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India – The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G P Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generic-led model to higher-value innovation.

The industry veterans highlighted how regulatory delays, especially in clinical trials, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plans to certify 1,000 clinical trial centres, signal intent, but more will be needed.

China emerged repeatedly as a point of comparison. Prasad said India had underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearances, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics



Eyeing a growth pill

■ Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad

■ Dr Reddy's Laboratories MD G P Prasad said India underestimated China, which built innovation strength through faster approvals

■ Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance

■ Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental trials.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately be a way for the industry and government to seek faster commercialisation such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, specialty generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant investment and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academy links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

• EXECUTIVE DIRECTOR Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldaworth.com before 3 March 2026

• EXECUTIVE DIRECTOR Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldaworth.com before 3 March 2026

• EXECUTIVE DIRECTOR Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is the largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MII).




MCX
METAL & ENERGY
Trade with Trust

Curators of the unique.

1 of 1

Exclusively Marketed By
India | Sotheby's
INTERNATIONAL REALTY



Villa in Moira, North Goa

For Sale

Plot size ≈ 4,200 sqm (≈ 1 acre) | Area ≈ 1,045 sqm (≈ 11,290 sq. ft.)

6 bedrooms



Scan to enquire

To schedule a viewing, contact:

Tushar Ahuja | +91 92899 68270

tushar.ahuja@sothebysrealty.in

26,100 Sales Associates | 1,100 Offices | 84 Countries & Territories

India Sotheby's International Realty is a trademark of Realpro Realty Solutions Pvt. Ltd.

No representations and warranties are made with respect to the completeness or accuracy of information concerning the property's size, amenities, facilities etc., which are published herein in good faith. The offerings are subject to errors, omissions, changes, including price, or withdrawal without notice. You are requested to get in touch with one of our agents via the contact details above.

Each Office is Independently Owned & Operated.



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

■ Submit KYC details to your bank

■ Bank uploads KYC details on Central KYC Records Registry

■ Can be used across banks & financial institutions

Know your CKYC ID

Missed call: 7799022129 or
Online: www.ckycindia.in

KEY BENEFITS

Open accounts easily with different banks/financial institutions
Simplifies KYC Updation: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYCR

**Simple.
Secure.
Standardised.**

for more details
visit <http://rbi.kothahai.rbi.org.in>
or feedback write to rbi.kothahai.rbi.org.in
Official WhatsApp
No. 99990 41935 / 99309 01935



Issued in public interest by
भारतीय रिजर्व बँक
RESERVE BANK OF INDIA
www.rbi.org.in